GeronFRA:GON -1.14%39 Market Cap is €709.8 Mil as of Jul. 02, 2026. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €6.03 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,427 Biotechnology companies, Geron ranks better than 77.51% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Geron's share price for the quarter that ended in Mar. 2026 was €1.2295. Geron's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 641.0 Mil. Therefore, Geron's market cap for the quarter that ended in Mar. 2026 was €788.2 Mil.
Geron's quarterly market cap
increased
from Sep. 2025 (€701.6 Mil) to Dec. 2025 (€727.8 Mil) and
increased
from Dec. 2025 (€727.8 Mil) to Mar. 2026 (€788.2 Mil).
Geron's annual market cap
increased
from Dec. 2023 (€1,056.6 Mil) to Dec. 2024 (€1,941.0 Mil) but then
declined
from Dec. 2024 (€1,941.0 Mil) to Dec. 2025 (€727.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Geron's Enterprise Value for Today is €542.7 Mil.
Geron (FRA:GON) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Geron Market Cap Related Terms
Geron Market Cap Historical Data
* Premium members only.
The historical data trend for Geron's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GON vs SPRY, PHAT, DSGN: Market Cap Comparison
For the Biotechnology subindustry, Geron's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's Market Cap distribution charts can be found below:
* The bar in red indicates where Geron's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Geron's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron (FRA:GON) has a Market Cap of €709.8 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Geron and its competitors. According to the industry distribution chart, Geron ranks #321 out of 1427 companies in the Biotechnology industry, placing it in the top 22.5%.
Is Geron's Market Cap too high?
Geron's current Market Cap is €709.8 Mil. Based on the distribution chart, Geron ranks #321 out of 1427 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Market Cap compare to SPRY and PHAT?
According to the Biotechnology industry distribution chart, Geron ranks #321 out of 1427 companies for Market Cap. This places Geron in the top 23% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Geron and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current Market Cap is €709.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €6.03, compared to a current price of €1.13 — trading 81.3% below its estimated fair value. The current Market Cap is €709.8 Mil. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Geron (FRA:GON), the current Market Cap is €709.8 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (FRA:GON) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.13 is trading 81.3% below its estimated GF Value™ of €6.03.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for FRA:GON:
Market Cap: €709.8 Mil
GF Value™: €6.03 vs. price of €1.13 (81.3% below fair value)
No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score
Get the complete analysis for FRA:GON
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GON has been successfully added to your 
